MedTrace Logo

Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins

NCT00839540 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2024-04-30

Study results available
· View outcomes & findings →

Summary

The purpose of this pharmacokinetic (PK) and pharmacodynamic (PD) study is:

To study the rate and duration of serum cidal activity of caspofungin (CFG) and micafungin (MFG) against Candida isolates from the subject and against Candida glabrata with varying degrees of caspofungin susceptibilities.

This investigation will provide clinicians information supporting the use of caspofungin and micafungin in situations where Candida strains may be a cause of infection.

Conditions

  • Candidemia

Interventions

DRUG

micafungin

100 mg qd by slow IV infusion for 24 h

DRUG

Micafungin

200 mg qd by slow IV infusion for 24 h

DRUG

Caspofungin

70 mg LD followed by 50 mg qd by slow IV infusion for 24 h

Sponsors & Collaborators

  • Astellas Pharma US, Inc.

    collaborator INDUSTRY

  • Gary E. Stein, Pharm.D.

    lead OTHER

Principal Investigators

  • Gary E Stein, Pharm.D. · Michigan State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00839540 on ClinicalTrials.gov